bcr-abl PCR response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in Stable Chronic Phase.
Primary Objective: Establish bcr-abl response to TKI therapy for chronic phase CML with stable molecular response.
Secondary Objectives: Observe molecular responses including complete molecular response of CML CP to TKI therapy with the agents such as imatinib, dasatinib, nilotinib and bosutinib
Primary endpoints: To evaluate log improvement in BCR-ABL blood quantitation after 1 year of combined TKI therapy.
Secondary endpoints: ? Evaluate Safety and Adverse Events. ? Evaluate compliance ? Proportion of Doses taken as per protocol,
Dose Limiting Toxicities. ? Evaluate Major Molecular Response (MMR) and Complete Molecular Remission (CMR) rate based on bcr-abl pcr for monitoring of CML at 3 monthly intervals while on TKI treatment for CML in chronic phase.